perflutren has been researched along with Wet Macular Degeneration in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Han, JM; Kang, HG; Kim, JH; Kim, KL; Kim, M; Kim, MS; Kim, SW; Lee, CS; Lee, JY; Park, SJ; Woo, SJ | 1 |
| Lee, K; Park, YG; Park, YH | 1 |
| Chang, W; Garg, SJ; Gupta, SA; Ho, AC; Hsu, J; Maturi, R; Regillo, CD; Sivalingam, A | 1 |
| Cho, HJ; Han, JI; Kim, HS; Kim, JH; Kim, JW; Koh, KM; Lee, TG; Lew, YJ | 1 |
| Byeon, SH; Lee, JM; Shin, JY | 1 |
| Cereda, MG; de Jong, JH; Faridpooya, K; van Meurs, JC; van Velthoven, ME; van Zeeburg, EJ; Vermeer, KA | 1 |
| Barr, CC; Fassbender, JM; Schaal, S; Sherman, MP | 1 |
| Kitagawa, Y; Mori, R; Shimada, H; Tanaka, K; Yuzawa, M | 1 |
| Bindra, MS; de Silva, SR | 1 |
| Kim, YM; Koh, HJ; Lee, SJ | 1 |
| Jackson, TL; Liazos, E; McHugh, D; Papavasileiou, E; Steel, DH | 1 |
1 trial(s) available for perflutren and Wet Macular Degeneration
| Article | Year |
|---|---|
INTRAVITREAL VERSUS SUBRETINAL ADMINISTRATION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR COMBINED WITH GAS FOR ACUTE SUBMACULAR HEMORRHAGES DUE TO AGE-RELATED MACULAR DEGENERATION: An Exploratory Prospective Study.
Topics: Acute Disease; Combined Modality Therapy; Endotamponade; Fibrinolytic Agents; Fluorocarbons; Humans; Injections, Intraocular; Intravitreal Injections; Prospective Studies; Recombinant Proteins; Retinal Hemorrhage; Tissue Plasminogen Activator; Tomography, Optical Coherence; Visual Acuity; Vitrectomy; Wet Macular Degeneration | 2016 |
10 other study(ies) available for perflutren and Wet Macular Degeneration
| Article | Year |
|---|---|
MACULAR HOLE ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION: Pathogenesis and Surgical Outcomes.
Topics: Aged; Endotamponade; Female; Fluorocarbons; Geographic Atrophy; Humans; Male; Middle Aged; Retinal Perforations; Retrospective Studies; Silicone Oils; Sulfur Hexafluoride; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Vitrectomy; Wet Macular Degeneration | 2021 |
VISUAL PROGNOSIS AFTER PNEUMATIC DISPLACEMENT OF SUBMACULAR HEMORRHAGE ACCORDING TO AGE-RELATED MACULAR DEGENERATION SUBTYPES.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Choroidal Neovascularization; Endotamponade; Female; Fluorescein Angiography; Fluorocarbons; Humans; Intravitreal Injections; Male; Middle Aged; Prognosis; Retinal Hemorrhage; Retrospective Studies; Supine Position; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2020 |
Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Air; Angiogenesis Inhibitors; Combined Modality Therapy; Endotamponade; Female; Fibrinolytic Agents; Fluorescein Angiography; Fluorocarbons; Humans; Injections, Intraocular; Male; Middle Aged; Prone Position; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tissue Plasminogen Activator; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitrectomy; Wet Macular Degeneration | 2014 |
Intravitreal ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Coloring Agents; Combined Modality Therapy; Endotamponade; Female; Fluorescein Angiography; Fluorocarbons; Humans; Indocyanine Green; Intravitreal Injections; Male; Middle Aged; Ranibizumab; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2015 |
Anti-vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Endotamponade; Female; Fluorescein Angiography; Fluorocarbons; Follow-Up Studies; Humans; Intravitreal Injections; Male; Ranibizumab; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2015 |
TISSUE PLASMINOGEN ACTIVATOR FOR SUBFOVEAL HEMORRHAGE DUE TO AGE-RELATED MACULAR DEGENERATION: Comparison of 3 Treatment Modalities.
Topics: Aged; Aged, 80 and over; Endotamponade; Exudates and Transudates; Female; Fibrinolytic Agents; Fluorocarbons; Fovea Centralis; Humans; Intravitreal Injections; Male; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tertiary Care Centers; Tissue Plasminogen Activator; Tomography, Optical Coherence; Visual Acuity; Vitrectomy; Wet Macular Degeneration | 2016 |
Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Choroidal Neovascularization; Combined Modality Therapy; Endotamponade; Female; Fibrinolytic Agents; Fluorescein Angiography; Fluorocarbons; Humans; Intravitreal Injections; Male; Middle Aged; Polyps; Prone Position; Prospective Studies; Ranibizumab; Retinal Hemorrhage; Tissue Plasminogen Activator; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2016 |
Early treatment of acute submacular haemorrhage secondary to wet AMD using intravitreal tissue plasminogen activator, C3F8, and an anti-VEGF agent.
Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Endotamponade; Female; Fibrinolytic Agents; Fluorocarbons; Humans; Intravitreal Injections; Male; Ranibizumab; Retinal Hemorrhage; Retrospective Studies; Secondary Prevention; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2016 |
Gas-assisted release of vitreomacular adhesion in wet age-related macular degeneration.
Topics: Fluorocarbons; Humans; Intraocular Pressure; Intravitreal Injections; Prone Position; Retinal Diseases; Risk Factors; Tissue Adhesions; Tomography, Optical Coherence; Vitreous Body; Vitreous Detachment; Wet Macular Degeneration | 2011 |
Intravitreal tissue plasminogen activator, perfluoropropane (C3F8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Choroid Diseases; Combined Modality Therapy; Endotamponade; Female; Fibrinolytic Agents; Fluorocarbons; Humans; Intravitreal Injections; Male; Middle Aged; Photochemotherapy; Polyps; Prone Position; Ranibizumab; Retinal Hemorrhage; Retrospective Studies; Tissue Plasminogen Activator; Tomography, Optical Coherence; Visual Acuity; Wet Macular Degeneration | 2013 |